Evaluation of a nutraceutical for prevention of equine ulcer recurrence
Equine Veterinary Journal · 2025
DOI: 10.1002/evj.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Equine Veterinary Journal, 2025. Verfasst von Sanni Hansen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark. Hauptthemen laut MEDLINE: Dietary Supplements, Horse Diseases, Stomach Ulcer. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Statera horsecare.
Abstract (Originalsprache)
Background
The number of horses with equine squamous gastric disease (ESGD) and equine gastric glandular disease (EGGD) recurrence when pharmacological treatment is discontinued is high.
Objective
To examine if a commercially available nutraceutical compound containing lecithin, pectin, and meadowsweet could prevent recurrence of both ESGD and EGGD after omeprazole treatment, evaluated by repeated gastroscopic examinations and saliva biomarkers. Study design Blinded, randomised, placebo‐controlled clinical trial.
Methods
Thirty horses of mixed breeds and sex with a recent diagnosis and treatment of both ESGD and EGGD were included and randomly assigned to a placebo or a nutraceutical group. The horses received 10 mL per 100 kg bodyweight (bwt) of either nutraceutical or placebo orally for the 4–8‐week duration of the study and were kept in their home environment and trained as normal. Gastroscopic grading of ESGD and EGGD and saliva were obtained at the initial diagnosis, as well as before and after the trial. Salivary biomarkers were measured by automated chemistry analysers using commercial kits. Due to the non‐normal distribution of data, Friedman tests with Wilcoxon post hoc tests were applied to assess changes over time within groups, Mann–Whitney U tests were performed to evaluate difference between groups.
Results
Regardless of nutraceutical or placebo assignment, only five horses remained ulcer free after the trial. The nutraceutical was not found to be better than placebo for preventing gastric disease recurrence when evaluated by gastroscopy scores. At the time of the last gastroscopy, the nutraceutical group had lower salivary ADA and higher bicarbonate concentrations compared to the placebo group. Main limitations Salivary biomarkers need further validation.
Conclusion
Although addition of the nutraceutical did not have a significant effect in preventing ESGD or EGGD recurrence, it produced changes in salivary biomarkers suggesting a potential improvement in gastric mucosal health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
- Interdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain.
ORCID-Profile: Sanni Hansen, Helena Carstensen
Förderung
- Statera horsecare
Zitieren
APA
Hansen, S., Tecles, F., Cerón, J. J., From, C., Carstensen, H., & Muñoz-Prieto, A. (2025). Evaluation of a nutraceutical for prevention of equine ulcer recurrence. Equine Veterinary Journal. https://doi.org/10.1002/evj.70143
Vancouver
Hansen S, Tecles F, Cerón JJ, From C, Carstensen H, Muñoz-Prieto A. Evaluation of a nutraceutical for prevention of equine ulcer recurrence. Equine Veterinary Journal. 2025. doi:10.1002/evj.70143
BibTeX
@article{Hansen2025,
author = {Hansen, Sanni and Tecles, Fernando and Cerón, José Joaquín and From, Cecilie and Carstensen, Helena and Muñoz-Prieto, Alberto},
title = {Evaluation of a nutraceutical for prevention of equine ulcer recurrence},
journal = {Equine Veterinary Journal},
year = {2025},
doi = {10.1002/evj.70143}
}
EUVIMED